In a report released on August 9, Anupam Rama from J.P. Morgan maintained a Buy rating on Kiniksa Pharmaceuticals (KNSA – Research Report), with a price target of $24.00. The company’s shares closed yesterday at $17.10.
According to TipRanks, Rama is a 4-star analyst with an average return of 2.9% and a 45.43% success rate. Rama covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Syndax Pharmaceuticals, and Kodiak Sciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Kiniksa Pharmaceuticals with a $26.75 average price target, a 56.43% upside from current levels. In a report released on July 25, Goldman Sachs also maintained a Buy rating on the stock with a $32.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $20.65 and a one-year low of $10.14. Currently, Kiniksa Pharmaceuticals has an average volume of 538.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason, and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.
Read More on KNSA:
